Dash Bio — Valuation, Funding & Investors

Recent changes

Aug 3, 2026Aug 3, 2026Raised $30M AlleyWatch
Aug 3, 2026Aug 3, 2026Dash Bio Raises $30M to Rebuild Drug Development Infrastructure Pulse story
Jun 15, 2026Jun 15, 2026Raised $30M SEC EDGAR Form D

Funding History

2 events · sources dated per row

Date	Event	Amount	Valuation	Investors	Source
Aug 3, 2026	funding round	$30M	—		Pulse story
Jun 15, 2026	funding round	$30M	—		SEC EDGAR Form D

Latest Pulse

Aug 3, 2026Dash Bio Raises $30M to Rebuild Drug Development InfrastructureDash Bio raised $30 million to build software infrastructure for drug development, part of a small but genuine wave of AI-native infrastructure plays targeting biotech's notoriously fragmented data and workflow problems.→

Coverage Timeline

newest first

Aug 3, 2026FUNDINGDash Bio Raises $30M to Rebuild Drug Development Infrastructure→

All Coverage

FUNDING· Aug 3, 2026

Dash Bio Raises $30M to Rebuild Drug Development Infrastructure

FUNDING

Dash Bio Raises $30M to Rebuild Drug Development Infrastructure

Dash Bio raised $30 million to build software infrastructure for drug development, part of a small but genuine wave of AI-native infrastructure plays targeting biotech's notoriously fragmented data and workflow problems.

Aug 3, 2026

Related Companies

Same sector

Attovia Therapeutics Apnimed Braveheart Bio Latigo Biotherapeutics Scribe Therapeutics

Sources & methodologyshow

Where these figures come from

SEC EDGAR Form Dprimary source1 fact
AlleyWatchValue Add VC data1 fact

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data · Suggest a correction